An observational study in Critical Illness and Cirrhosis, Liver, sponsored by University Hospital, Lille. Recruiting at 2 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by University Hospital, Lille · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Liver Cirrhosis with a site in France — 22 open to participants now, 25 under way, 2 of them phase 3. Liver Cirrhosis · France.
Among the 95 studies in Liver Cirrhosis with a site in France, this one is the 22nd largest by planned enrollment of the 41 observational ones that give a count, is one of 5 that started in 2021, is one of 41 observational ones, reaches primary completion later than 6 of the 24 other live ones, and was the 53rd registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →22 of the 95 studies in Liver Cirrhosis with a site in France are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in France, Austria, Belgium and 9 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 16 · Phase 3 10
First in 2002; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 226 is above the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 205 across the 53 interventional studies, 227 across the 41 observational. Of the 63 that completed or were terminated, 11 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
University Hospital, Lille has 2 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Liver Cirrhosis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT04530760University Hospital, LilleIntraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation | 2026-12 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07439939Assistance Publique - Hôpitaux de ParisExploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement | 2027-06-09 |
Add all 8 to your calendar (.ics) → With an account.
Among the 95 studies in Liver Cirrhosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to demonstrate the relationship between intra-abdominal hypertension (IAH) and abundant microaspirations in mechanically ventilated cirrhotic.
Intra-abdominal pressure monitoring will be performed using intra-vesical pressure every 8 hour in the first 2 days of mechanical ventilation.
Micro aspiration is defined by pepsin or amylase positivity in trachea suction. Two groups will be compared : one with IAH , one without IAH.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
This study's planned enrollment of 226 is above the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Browse Liver Cirrhosis studies →University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
Compared within Liver Cirrhosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
cirrhotic patients receiving invasive mechanical ventilation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients with intraabdominal hypertension defined as intravesical pressure more than 12 mmHg
patients with no intraabdominal hypertension
abundant microaspiration
presence of pepsin or alpha amylase at significant level in at least 30% of tracheal aspirates
Time frame: 48 hours after inclusion
Mortality
number of death
Time frame: from ICU admission until day 28
Incidence of ventilator associated pneumonia (VAP)
percentage of patients with VAP
Time frame: from intubation until day 28 or extubation
duration of mechanical ventilation
number of days with mechanical ventilation
Time frame: from intubation until day 28 or extubation
incidence of patients requiring renal replacement therapy
percentage of patients with renal replacement treatment
Time frame: from ICU admission until Day 28 or ICu discharge, whichever came first
incidence of cirrhosis related complications
percentage of patients with cirrhosis related complications
Time frame: from ICU admission until Day 28 or ICU discharge, whichever came first
Started Oct 2021 (actual). Primary completion is estimated for Dec 2026, 62 months after the start.
Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 62 months is above that.
Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.